Annexon, Inc. ANNX
4.20 USD +0.20 (+4.87%)
At closeNov 6, 2026, 5:02 PM EST
4.20 0.00 0.00%
After hours · Nov 6, 5:02 PM ET
4.04 Day range 4.29
2.68 52-week range 6.96
- YTD
- -16.33%
- 1 year
- +39.07%
News
marketbeat.com Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug Annexon NASDAQ: ANNX said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of…
seekingalpha.com Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript
benzinga.com Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026.…
benzinga.com Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
benzinga.com HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25 HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
benzinga.com JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15 JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $15.- benzinga.com JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14 JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
benzinga.com Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34)…
benzinga.com Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…
benzinga.com Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved…
benzinga.com Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…- benzinga.com Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3 Citizens analyst Jonathan Wolleben initiates coverage on Annexon (NASDAQ:ANNX) with a Market Underperform rating and announces Price Target of $3.
benzinga.com Needham Maintains Buy on Annexon, Raises Price Target to $25 Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $11 to $25.- benzinga.com Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people…
- benzinga.com Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7 Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral rating and announces Price Target of $7.
benzinga.com Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 37.84 percent increase over losses of $(0.37) per…
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 221 companies hit new 52-week lows.
- benzinga.com Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's morning session, 234 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 78 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 81 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 147 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 63 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 454 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 107 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 348 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 147 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
- benzinga.com Stocks Hitting New 52-Week Lows Today On Monday morning, 60 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 173 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning trading, 285 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday morning saw 331 companies set new 52-week highs.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2021